Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next [Yahoo! Finance]
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: Yahoo! Finance
in Alzheimer's disease, while also confirming that its data package for AXS-12 in narcolepsy is sufficient to support a New Drug Application filing. These twin regulatory milestones highlight Axsome's growing late-stage CNS pipeline breadth, with potential for expanded indications that could reshape its long-term revenue mix if approvals are ultimately secured. Next, we'll examine how FDA priority review for AXS-05 could influence Axsome's late-stage CNS pipeline narrative and future growth profile. These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Axsome Therapeutics, you need to believe its expanding CNS portfolio can eventually support a broader, more durable revenue base beyond Auvelity and Sunosi, while the company manages ongoing losses and high spend. The new FDA priority review for AXS-05 in Alzheimer's agitation now stands out as the key n
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product RevenueGlobeNewswire
- Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
AXSM
Earnings
- 11/3/25 - Miss
AXSM
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 144
- AXSM's page on the SEC website